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The greater omentum is an uncommon location for primary tumors. Metastatic tumors of the omentum are common.
In contrast, primary tumors of the omentum are very rare. Sporadic cases of primary rhabdomyosarcoma (RMS) arising
in the abdomen have been reported, but these cases are limited almost exclusively to the pediatric population. We
report a well-documented case of primary intra-abdominal RMS in a 21-year-old man who presented with complaints
of abdominal pain and lump in left hypochondrium region. Imaging revealed it to be a large mass in the left
hypochondrium region displacing the bowel loops. Further investigations revealed omental RMS. The mass had
originated from the greater omentum and was excised. Our case is doing well and is presently receiving chemotherapy.
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RMS is an uncommon neoplasm in the adult population.
The name is derived from the Greek words rhabdo,
which means rod shape, and myo, which means muscle.
Sporadic cases of primary RMS arising in the abdomen
have been reported, but these cases are limited almost
exclusively to the pediatric population. Intraperitoneal
RMS, and in particular with omental involvement, in
any age has been rarely reported in literature. RMS usu-
ally manifests as an expanding mass. Tumors in superfi-
cial locations may be palpable and detected relatively
early, but those in deep locations (e.g., retroperitoneum)
may grow large before causing symptoms. Cells are usu-
ally positive for intermediate filaments and other pro-
teins typical of differentiated muscle cells, such as
desmin, vimentine, myoglobin, actin, and transcription
factor myoD. Treatment responses and prognoses widely
vary depending on location and histology. While the op-
timal management of this rare tumor is unknown, early
recognition and diagnosis, and a prompt multimodality
treatment approach of surgery, chemotherapy, and
radiotherapy offers the best chance of cure.* Correspondence: priyank56pathak@yahoo.co.in
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A 21-year-old-man was admitted to our hospital with a
1-month history of abdominal pain. Physical examin-
ation revealed a palpable mobile lump in the left hypo-
chondrium region and extending up to the epigastrium
region. There is no past history of any surgical interven-
tions and any chronic illness. No positive family history
of any hereditary disease or any carcinoma. No abnor-
malities in routine blood workup. Ultrasound abdomen
was suggestive of a well defined but irregular hypoechoic
mass lesion in the left hypogastric region and extending
into the lumbar region. Colonoscopy was done which
was negative for any intramural growth and no signs of
malignancy. Ultrasound guided FNAC from the left
hypochondrium region showed deposits of adenocarcin-
oma. The abdominal CT revealed a large well defined
mass lesion in the left hypochondrium, measuring 9.8
× 7.4 cms, causing displacement of the bowel loops
(Fig. 1).
Intraoperative, a large hard, nodular necrotic mass
encased within the greater omentum present at the
splenic flexure. Some peri splenic and para aortic lymph
nodes were present which were excised in block (Fig. 2).
The histopathological diagnosis of the patient was re-
ported as poorly differentiated malignant round cellis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Showing a large well defined mass of 9.8 × 7.4 cms along with displacement of the bowel loops
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nodal extension. Lymph nodes were free of tumor, and
there was only reactive hyperplasia. On cross section
examination, cut surface was homogenous grayish white
along with many areas of hemorrhage and necrosis. On
microscopy, tumor cells have round to mildly pleo-
morphic nuclei, with coarse chromatin and indistinct
cell borders. Large areas of tumor necrosis are seen
(Fig. 3).
Immunohistochemistry was planned in view of mul-
tiple differential diagnoses in the histopathological re-
port. Immunohistochemistry revealed strong staining for
Vimentin, EMA, and desmin, thereby confirming the
diagnosis for RMS (Figs. 4 and 5). The postoperativeFig. 2 Intra operative finding of a large omental tumor in the left
hypochondrium region with areas of ulcerationperiod was uneventful. Postoperatively, upper gastro-
intestinal endoscopy was done which was normal. He
was discharged on the third postoperative day. Patient
underwent PET scan, which turned out to be negative
for any primary disease or other secondary deposits. Pa-
tient is undergoing chemotherapy (4 cycles). Patient is
presently on vincristine, dactinomycin, and ifosfamide
regimen (vincristine: 1.5 mg/m2 iv on day 1, dactinomy-
cin 0.75 mg/m2 iv on day 1 and 2, mesna prior to ifosfa-
mide 1gm/m2 on day 1 and 2, and then ifosfamide
1.5gm/m2 iv on day 1 and 2). Patient is doing well and
has completed all the cycles of chemotherapy. Blood in-
vestigations done routinely are all within normal limits.
Patient has been counseled to come for follow up everyFig. 3 H and E; 10 × 10 X shows malignant round cell tumor
arranged in sheets admixed with areas of necrosis
Fig. 4 Immunohistochemistry, 10 × 10 X shows tumor cells showing
desmin positivity
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pected survival age of the patient.
Discussion
Contrary to metastatic tumors of the omentum, pri-
mary tumors of the omentum are very rare and
sporadically reported. However, a primary malignant
rhabdoid tumor in the omentum is very rare. RMS
rarely affects adults. AS per the Pubmed survey, only
three cases have been reported yet. The rhabdoid
cells show round to tear drop shape with vesicular
nuclei and a single large nucleolus. There are ill-
defined round to oval hyaline inclusions composed
of intermediate filaments in cytoplasm [1].
Intraperitoneal RMS, and in particular with omental
involvement, in any age has been rarely reported in
literature [2]. In general, the symptoms of omentalFig. 5 Immunohistochemistry 10 × 10 X shows tumor cells are
negative for pancytokeratintumors present as abdominal discomfort (45.5 %), ab-
dominal mass (34.9 %), and abdominal distention
(15.2 %). Unfortunately, there are no specific findings
differentiating the origin or nature of the mass in im-
aging studies due to the extent of the omentum and
the adhered organs. A considerable finding is dis-
placement of the stomach, the transverse colon, and
small bowel, by an extrinsic mass [3].
The treatment of omental tumors is complete excision
via omentectomy. We diagnosed the mass as a malig-
nant rhabdoid tumor based on the typical cellular
morphology and immunohistochemical stains. Immuno-
histochemically, the rhabdoid cells express both cytoker-
atin and vimentin, but not myogenic differentiation nor
INI1 protein [4].
For treatment, an aggressive operation to achieve total
resection is recommended because the effectiveness of
chemo radiotherapy has not been proven. The classic
combination of ifosfamide, carboplatinum, and etoposide
is recommended, and multidrug protocols including
topoisomerase I inhibitors are recommended [5].
Vincristine, actinomycin, and cyclophosphamide (VAC)
compared with vincristine, Actinomycin, and Cyclophos-
phamide with Vincristine, topotecan, and cyclophospha-
mide (VAC/VTC) for intermediate rhabdomyosarcoma
was done at weeks 3, 9, 21, 27, 33, 39 did not show an im-
provement in outcome for patients with intermediate-risk
RMS. The estimated 4-year FFS rates were 73 % for VAC
and 68 % for VAC/VTC, which did not differ significantly
[6].
Radiotherapy plays an important role in the treatment
of RMS and is a major tool in the treatment of children.
A cumulative dose of between 36 and 41.4 Gy is gener-
ally sufficient to control microscopic residual disease,
and doses of between 50.4 and 54 Gy are utilized to con-
trol gross residual disease. Patient is to be followed every
3 months for the 1st year, then every 6 months for the
2nd and 3rd year and then yearly after [7].
Conclusions
The diagnosis of tumors in the omentum is very difficult
and requires confirmation by excision and histologic
evaluation. A primary tumor originating in the omentum
is rare but possible even as a malignant tumor. The
prognosis depends mainly on tumor biology yet the ma-
lignancy of the omentum might cause severe outcomes
because these masses can easily metastasize to mesen-
tery and peritoneum tissues.
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